Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyPremera Bluecross IVIG/SCIG Coverage Update | Open…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 8.01.503

    Immune Globulin Therapy (IVIG/SCIG) Coverage and Site-of-Service Criteria

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 8.01.503 alerts

    Get alerted when Policy 8.01.503 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, site-of-service review rules, and clinical coverage criteria for intravenous and injectable immune globulin products; intended for providers requesting prior authorization for immune globulin administration.

    Policy Summary
    PayerPremera Bluecross
    PolicyImmune Globulin Therapy (IVIG/SCIG) Coverage and Site-of-Service Criteria
    Policy CodePolicy 8.01.503
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document diagnosis, age/platelet counts (for ITP), disease severity, and prior inadequate response to conventional agents when requesting IVIG.
    SourceLink
    POLICY UPDATE CHANGES

    This policy has been revised and effective Aug. 1, 2026.

    Site of Service Medical Necessity criteria do NOT apply to Alaska fully insured members; infusion/injection drug criteria apply instead.

    16+Drugs listed for SOS review
    <500IgG threshold (general)
    90dPreferred site period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <10k
    ITP platelet threshold
    3Major indication groups

    Coverage Criteria for Immune Globulin (IVIG/SCIG)

    Site-of-Service Medical Necessity

    Site-of-service rules apply to medical-benefit reviews and to members aged 13 years and older (with an Alaska fully insured exception). Covered site types and preferred-site timing are shown below.

    SOS applicability: Site-of-Service (SOS) medical necessity criteria apply to medical benefit reviews for individuals aged 13 years or older; SOS criteria do NOT apply to Alaska fully insured members.

    See policy statements on SOS applicability

    Medically necessary sites: Physician's office OR Infusion center OR Home infusion OR Hospital-based outpatient setting (outpatient hospital IV infusion department / hospital-based outpatient clinical level of care).

    Preferred medically necessary sites per policy

    Preferred first 90 days: Outpatient infusion at preferred sites is considered medically necessary for the initial course of an infusion/injection or for re-initiation of an agent after ≥6 months following discontinuation; this does NOT include standard dosing intervals that are ≥6 months.first 90 days

    Preferred site period described in policy

    When hospital-based outpatient site may be appropriate: Known cardiac or pulmonary condition with increased risk OR unstable renal function OR difficult/unstable vascular access OR acute mental status changes OR history of severe adverse reactions/anaphylaxis

    Examples of clinical reasons to use higher-level site

    CRS inpatient criteria: Cytokine release syndrome (CRS) grade 3–4 defined by fever ≥38°C AND hypotension requiring ≥1 vasopressor AND hypoxia requiring high‑flow oxygen or positive pressure; inpatient admission required when these criteria present.CRS grade 3-4

    Policy describes inpatient criteria for CRS

    IVIG — Primary Immunodeficiency and Specific Antibody Deficiency (SAD)

    IVIG for primary immunodeficiency and specific antibody deficiency (SAD) is covered only when ALL required laboratory and clinical criteria are met.

    Primary immunodeficiency diagnoses: Conditions include ataxia telangiectasia; common variable immunodeficiency; congenital agammaglobulinemia; severe combined immunodeficiency; Wiskott–Aldrich syndrome; X‑linked agammaglobulinemia; X‑linked hyperimmunoglobulinemia.

    List from policy

    Lab criteria for primary immunodeficiency: Agammaglobulinemia (total IgG <200 mg/dL) OR persistent hypogammaglobulinemia (total IgG <500 mg/dL or ≥2 SD below normal on at least 2 occasions) OR absence of B lymphocytes.IgG <200 mg/dL OR IgG <500 mg/dL

    Laboratory thresholds specified in policy

    Functional immune response: Documented inability to mount an adequate immunologic response to antigens (e.g., lack of appropriate rise in antibody titer after provocation with a protein antigen).

    Functional testing requirement from policy

    IVIG — Selected infections and other indications

    IVIG may be medically necessary for select infectious and acute indications when specified IgG thresholds or a documented diagnosis are present.

    Children with HIV — opportunistic infection prevention: IVIG may be considered when the child has IgG level <500 mg/dL to help prevent opportunistic infections.IgG <500 mg/dL

    Policy specifies IgG threshold for HIV-infected children

    Measles post-exposure prophylaxis (PEP): IVIG may be considered for measles post-exposure prophylaxis when IgG <500 mg/dL or when the documented clinical scenario indicates need.IgG <500 mg/dL

    Policy includes measles PEP with IgG threshold

    Severe anemia due to human parvovirus B19: IVIG may be considered medically necessary when there is a documented diagnosis of severe anemia associated with human parvovirus B19.

    IVIG — Autoimmune and inflammatory conditions (including mucocutaneous blistering and pemphigoid)

    IVIG for autoimmune and inflammatory conditions — especially autoimmune mucocutaneous blistering diseases — is considered only when ALL listed requirements are met.

    Severity requirement: The individual has severe progressive autoimmune mucocutaneous blistering disease.

    Severity must be documented per policy

    Prior therapy requirement: The individual has tried and had an inadequate response to conventional agents (corticosteroids and immunosuppressive agents such as azathioprine, cyclophosphamide, mycophenolate).

    Prior trials and inadequate response required

    Applicable blistering diagnoses: Pemphigoid (bullous pemphigoid, mucous membrane pemphigoid) OR Pemphigus (pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus).

    List of disease subtypes from policy

    Autoimmune mucocutaneous blistering diseases — Initial/conditional coverage

    Initial or conditional coverage for autoimmune mucocutaneous blistering diseases requires ALL of the following be documented.

    Listed diagnosis: Diagnosis of an autoimmune mucocutaneous blistering disease (e.g., bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus).

    Specific diagnoses must be documented

    Severe progressive disease: Disease is severe and progressive as documented in the medical record.

    Severity must be clearly documented

    Prior inadequate response to conventional agents: Prior trial and inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (examples: azathioprine, cyclophosphamide, mycophenolate).

    Prior therapies and inadequate response must be documented

    Measles PEP, Parvovirus B19 anemia, Toxic shock syndrome

    The following acute/infectious indications are covered when the documented diagnosis (or IgG threshold where specified) is present.

    Measles post-exposure prophylaxis: Documented indication for measles post-exposure prophylaxis OR IgG <500 mg/dL when specified.IgG <500 mg/dL (when indicated)

    Policy references measles PEP with IgG threshold

    Severe anemia from human parvovirus B19: Documented diagnosis of severe anemia associated with human parvovirus B19.

    Documented diagnosis required per policy

    Toxic shock syndrome (TSS): Documented diagnosis of toxic shock syndrome.

    Documented diagnosis required per policy

    Medically necessary indications and criteria

    The policy lists several medically necessary indications; IVIG is covered when the condition-specific conjunctive criteria below are satisfied.

    Listed indications (summary): Measles post-exposure prophylaxis; Severe anemia associated with human parvovirus B19; Toxic shock syndrome (TSS); Autoimmune mucocutaneous blistering diseases (pemphigoid and pemphigus subtypes).

    Each indication appears as individually sufficient when its criteria are met

    Autoimmune blistering two-part requirement: For autoimmune mucocutaneous blistering diseases, BOTH: (1) severe progressive disease AND (2) prior trial with inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate).

    Two conjunctive requirements repeated throughout policy

    IVIG considered medically necessary for listed diagnoses

    IVIG is considered medically necessary for the listed diagnoses only when ALL of the following core requirements are met.

    Core medical necessity requirements: 1) Individual has severe progressive disease (for autoimmune indications); AND 2) Individual has tried and had an inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, mycophenolate).

    Applies to autoimmune blistering diseases and referenced infectious/toxic diagnoses where indicated

    Autoimmune mucocutaneous blistering diseases — medical necessity

    Autoimmune mucocutaneous blistering diseases are covered when ALL of the following are met.

    Autoimmune blistering IVIG criteria: (1) Diagnosis is one of: bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, or paraneoplastic pemphigus; (2) The individual has severe progressive disease; (3) The individual has tried and had an inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, mycophenolate).

    Complete blistering disease criteria from policy

    Severe anemia due to human parvovirus B19 — medical necessity

    Severe anemia due to human parvovirus B19 is covered when the documented diagnosis is present.

    Parvovirus B19 anemia: Documented diagnosis of severe anemia associated with human parvovirus B19.

    Policy requires documented diagnosis

    Toxic shock syndrome (TSS) — medical necessity

    Toxic shock syndrome (TSS) is covered when the documented diagnosis is present.

    TSS: Documented diagnosis of toxic shock syndrome (TSS).

    Policy states IVIG may be considered with documented TSS

    Immune thrombocytopenia (adults) — medical necessity

    Adult immune thrombocytopenia (ITP) — IVIG may be considered medically necessary when ALL of the indicated elements below are met.

    Adult ITP — general requirement: Documented diagnosis of immune thrombocytopenia in an adult.

    Diagnosis must be documented

    Age requirement: Individual is aged 18 years or older.>= 18 years

    Policy specifies adult age threshold

    Platelet count and bleeding risk: Platelet count <10,000/mm³ with individual considered at risk for severe or intracranial bleeding OR alternate mentions in text of platelet count <30,000/mm³ in specific contexts; assess and document bleeding risk.<10,000/mm³ primary; <30,000/mm³ noted as alternate

    Policy repeats both thresholds and requires bleeding-risk assessment

    Autoimmune mucocutaneous blistering diseases (IVIG)

    IVIG for autoimmune mucocutaneous blistering diseases (IVIG) is covered when ALL of the following are documented.

    Blistering disease severity and prior therapy: The individual has severe progressive disease AND has tried and had an inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, mycophenolate).

    Both conditions required per policy

    Immune thrombocytopenia (IVIG)

    IVIG for adult immune thrombocytopenia (ITP) is covered when ALL of the following are documented.

    Age: Individual is aged 18 years or older.>=18 years

    Adult age threshold from policy

    Documented diagnosis: There is a documented diagnosis of immune thrombocytopenia (ITP).

    Diagnosis must be documented

    Platelet count and bleeding risk: Platelet count <10,000/mm³ and individual is considered at risk for severe or intracranial bleeding OR alternate mentions of platelet count <30,000/mm³ in specific contexts; bleeding-risk assessment should be documented.<10,000/mm³ primary; <30,000/mm³ alternate

    Numeric thresholds and bleeding risk per policy

    Toxic shock syndrome (IVIG)

    Toxic shock syndrome (IVIG) — covered when the documented diagnosis is present.

    TSS diagnosis: IVIG therapy may be considered medically necessary when toxic shock syndrome is the documented diagnosis.

    Documented diagnosis required per policy

    Indication-specific medical necessity

    Indication‑specific medical necessity — IVIG is covered when ALL criteria listed for each condition are met.

    Immune thrombocytopenia (adult): IVIG may be considered medically necessary for adult individuals with ITP when: the individual is aged 18 years or older; platelet counts and bleeding‑risk criteria are met; and a documented diagnosis is present.
    Toxic shock syndrome (TSS): IVIG may be considered medically necessary when TSS is the documented diagnosis.
    Autoimmune mucocutaneous blistering diseases: IVIG may be considered medically necessary when the individual has severe progressive disease AND has had an inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate).

    Indications: ITP-Adults; Autoimmune mucocutaneous blistering diseases; Toxic shock syndrome

    Coverage for the three major indication groups is described below; all listed elements must be documented.

    ITP — Adults: IVIG may be considered medically necessary for adults with immune thrombocytopenia when: (1) age ≥18 years; (2) platelet count <10,000/mm³; and (3) documented diagnosis and assessment of bleeding risk indicating risk for severe or intracranial bleeding.
    Autoimmune mucocutaneous blistering diseases: IVIG may be considered medically necessary when: (1) diagnosis is a listed pemphigoid or pemphigus subtype; AND (2) disease is severe and progressive; AND (3) prior trial and inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate) are documented.
    Toxic shock syndrome (TSS): IVIG may be considered medically necessary when TSS is the documented diagnosis.

    Autoimmune mucocutaneous blistering diseases (pemphigoid and pemphigus variants)

    Autoimmune mucocutaneous blistering diseases (pemphigoid and pemphigus variants) — covered when ALL of the following are met.

    Blistering disease criteria: 1) Diagnosis of a listed autoimmune mucocutaneous blistering disease (pemphigoid or pemphigus subtype); 2) Disease is severe and progressive; 3) Prior trial with inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate).

    Complete conjunctive criteria per policy

    Immune thrombocytopenia (ITP) — Adults

    Adult ITP — IVIG is covered when ALL of the following are documented.

    Adult ITP IVIG criteria: 1) Individual is aged 18 years or older; 2) Platelet count is less than 10,000/mm³; 3) Individual is considered at risk for severe bleeding or intracranial bleeding; 4) Documented diagnosis of ITP.platelet <10,000/mm³; age >=18 years

    Policy requires numeric platelet threshold and bleeding-risk assessment

    Toxic shock syndrome (TSS)

    Toxic shock syndrome (TSS) — IVIG covered when documented diagnosis present.

    TSS coverage: Documented diagnosis of toxic shock syndrome.

    Policy states documented diagnosis is sufficient

    Autoimmune mucocutaneous blistering diseases (Pemphigoid, Pemphigus)

    Pemphigoid and pemphigus IVIG coverage — ALL required elements must be present.

    Pemphigoid/pemphigus IVIG criteria: 1) Documented diagnosis of a listed pemphigoid or pemphigus subtype; 2) Severe progressive disease; 3) Prior trial and inadequate response to conventional agents (e.g., corticosteroids, azathioprine, cyclophosphamide, mycophenolate).

    Policy repeats these requirements

    Immune thrombocytopenia (ITP) - Adults

    Adult ITP (detailed) — covered when ALL listed criteria are documented.

    ITP detailed criteria: 1) Individual is aged 18 years or older; 2) Platelet count is less than 10,000/mm³; 3) Individual is considered at risk for severe bleeding or intracranial bleeding; 4) Documented diagnosis of ITP.platelet <10,000/mm³; age >=18 years

    Detailed adult ITP criteria from policy

    Toxic shock syndrome (TSS)

    Toxic shock syndrome (TSS) — covered when documented diagnosis present.

    TSS documented diagnosis: Documented diagnosis of toxic shock syndrome; IVIG may be considered medically necessary when this diagnosis is present.

    Policy requirement: documented diagnosis

    Autoimmune mucocutaneous blistering diseases (pemphigoid, pemphigus)

    Autoimmune mucocutaneous blistering diseases — repeated articulation of the conjunctive criteria for coverage.

    Blistering disease conjunctive criteria: 1) Severe progressive disease; AND 2) Tried and had an inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, mycophenolate); AND 3) Diagnosis is a listed pemphigoid or pemphigus subtype.

    Repeated policy language consolidated here

    Immune thrombocytopenia (ITP) — Adults

    Adult ITP — IVIG covered when ALL of the following are documented (including bleeding‑risk assessment).

    Adult ITP coverage: 1) Individual is aged 18 years or older; 2) Platelet count is less than 10,000/mm³ AND the individual is considered at risk for severe bleeding or intracranial bleeding; 3) Documented diagnosis of ITP.Platelet <10,000/mm³; age >=18 years

    Bleeding-risk assessment required per policy

    Autoimmune mucocutaneous blistering diseases

    Autoimmune mucocutaneous blistering diseases — covered when ALL of the following are met (restated).

    Autoimmune blistering disease criteria (restated): 1) Listed autoimmune mucocutaneous blistering disease (pemphigoid or pemphigus variant); 2) Severe progressive disease; 3) Prior trial and inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate).

    Policy restates these conjunctive requirements

    Immune thrombocytopenia (ITP) — Adults

    Adult ITP — IVIG considered medically necessary when ALL of the following are documented (alternate wording present in source).

    Adult ITP criteria (alternate wording): 1) Individual is aged 18 years or older; 2) Platelet count less than 10,000/mm³; 3) Individual is considered at risk for severe bleeding or intracranial bleeding; 4) Documented diagnosis of ITP.age >=18; platelet <10,000/mm³

    Policy repeats numeric thresholds across sections

    IVIG for adult immune thrombocytopenia (ITP)

    IVIG for adult ITP — covered when ALL of the following are present (policy notes alternate platelet threshold mentions).

    Adult ITP IVIG criteria: 1) Individual is aged 18 years or older; 2) Platelet count <10,000/mm³ and individual is considered at risk for severe or intracranial bleeding OR portions of the text reference platelet count <30,000/mm³ as an alternate threshold; 3) Documented diagnosis of ITP.

    IVIG for autoimmune mucocutaneous blistering diseases

    IVIG for autoimmune mucocutaneous blistering diseases — covered when ALL of the following are documented.

    Blistering disease IVIG criteria: 1) Diagnosis among listed pemphigoid or pemphigus subtypes; 2) Severe progressive disease; 3) Prior trial and inadequate response to conventional agents such as corticosteroids and immunosuppressive agents (examples: azathioprine, cyclophosphamide, mycophenolate).

    Initial therapy criteria

    Initial therapy criteria — IVIG may be considered medically necessary for each indication when ALL listed criteria for that indication are met.

    ITP - Adults (initial therapy): IVIG may be considered medically necessary for adults with ITP when: (1) age ≥18 years; AND (2) platelet count <10,000/mm³ with individual at risk for severe or intracranial bleeding OR platelet count <30,000/mm³ as an alternate mention; AND (3) documented diagnosis of ITP.
    Autoimmune mucocutaneous blistering diseases (initial therapy): IVIG may be considered medically necessary when: (1) diagnosis is a listed pemphigoid or pemphigus subtype; (2) disease is severe and progressive; AND (3) prior trial and inadequate response to conventional agents (corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate) are documented.

    Medically necessary indications (partial)

    Summary: IVIG is medically necessary for the listed condition groups when the condition-specific criteria below are documented.

    Autoimmune mucocutaneous blistering diseases: Condition is a listed pemphigoid (bullous or mucous membrane) OR pemphigus (vulgaris, foliaceus, IgA pemphigus, paraneoplastic) AND the individual has severe progressive disease AND has tried and had an inadequate response to conventional agents such as corticosteroids and immunosuppressives (e.g., azathioprine, cyclophosphamide, mycophenolate).

    Documentation of prior therapy failure and severity required

    Immune thrombocytopenia (ITP) - Adults: Individual is aged ≥18 years AND either: platelet count <10,000/mm³ with individual at risk for severe or intracranial bleeding OR platelet count <30,000/mm³ (alternate mention); documented diagnosis of ITP required.age >=18; platelets <10,000 OR <30,000

    Documented diagnosis and bleeding-risk assessment required

    For site-of-service determinations, the policy specifies preferred outpatient settings (physician office, infusion center, or home infusion) and allows hospital-based outpatient infusion only when medically indicated. Use of an outpatient hospital IV infusion department is not medically necessary when the policy's site-of-service criteria are not met; the hospital‑based outpatient site is considered medically necessary for the initial course or re‑initiation after ≥6 months or when specific clinical risks are present. Documentation should therefore demonstrate why a non‑preferred site is required (for example: known cardiac or pulmonary condition, unstable renal function, difficult/unstable vascular access, acute cognitive impairment affecting safety, history of severe adverse reactions/anaphylaxis, or grade 3–4 cytokine release syndrome with planned inpatient admission).

    The excerpted policy sections do not present a separate explicit list of exclusions for IVIG use. Instead, coverage is defined positively by indication‑specific medical necessity criteria (for example, documented diagnoses such as measles post‑exposure prophylaxis, severe anemia from parvovirus B19, toxic shock syndrome, or specified autoimmune mucocutaneous blistering diseases) and by meeting the stated clinical and prior‑therapy requirements.

    No additional explicit exclusions are stated in these document excerpts beyond the site‑of‑service guidance and the implication that IVIG is not medically necessary when the written criteria are unmet. The policy emphasizes condition‑specific coverage rules and required documentation (diagnosis, severity, prior trials of conventional agents, platelet counts and bleeding‑risk assessment for ITP) rather than enumerating standalone exclusions.

    Drugs Subject to Site-of-Service Review and Clinical Thresholds

    Drugs subject to site-of-service reviewmixed
    AlygloProduct listed for site-of-service review
    AscenivProduct listed for site-of-service review
    BivigamProduct listed for site-of-service review
    CutaquigProduct listed for site-of-service review
    CuvitruProduct listed for site-of-service review
    Flebogamma DIFProduct listed for site-of-service review
    GammagardProduct listed for site-of-service review
    GammakedProduct listed for site-of-service review
    GammaplexProduct listed for site-of-service review
    Gamunex-CProduct listed for site-of-service review
    1–10 of 17
    1/2
    IgG level thresholds for immunodeficiency indications
    General immunodeficiency thresholdTotal IgG < 500 mg/dL
    Agammaglobulinemia thresholdTotal IgG < 200 mg/dL
    Measurement requirementPersistent hypogammaglobulinemia defined as IgG < 500 mg/dL on at least 2 occasions or ≥2 SD below normal
    Age threshold — adult (ITP)
    Adult age cutoff for ITP criteriaIndividual is aged 18 years or older
    Applies to IVIG for ITPAge ≥18 required when requesting IVIG for adult immune thrombocytopenia

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Pre-approval required for IVIG

    IVIG generally requires pre-approval by the health plan; requests must document the clinical and laboratory criteria relevant to the indication (e.g., IgG thresholds or other diagnostic evidence) to establish medical necessity.

    Prior Authorization

    Prior authorization when documentation requires severity/prior treatment

    When the indication requires showing severe progressive disease or prior inadequate response to conventional agents, prior authorization must include documentation demonstrating those clinical findings.

    • Show evidence of severe progressive disease where applicable
    • Document trials and inadequate response to conventional therapies
    Prior Authorization

    Background on Immune Globulin Therapy

    Immune globulins are plasma‑derived antibody preparations used either to replace deficient immunoglobulins or to modulate immune responses. Intravenous (IVIG) and subcutaneous (SCIG) formulations are employed in primary immunodeficiency states to prevent infections and in selected infectious, autoimmune, and inflammatory conditions. The policy describes common IVIG uses including replacement therapy for immunodeficiency (with defined IgG thresholds and functional antibody criteria) and therapeutic use for specific indications such as measles post‑exposure prophylaxis, severe anemia from human parvovirus B19, toxic shock syndrome (TSS), and severe, progressive autoimmune mucocutaneous blistering diseases (e.g., pemphigoid and pemphigus variants) when conventional therapies have failed.

    Definitions and Key Terms

    Immune globulin therapy — definition
    DefinitionInfusion or injection of concentrated plasma-derived antibodies to provide passive immunity or modulate immune responses.
    PurposeUsed to replace deficient immunoglobulins or modulate immune function in select conditions
    RoutesAdministered intravenously (IVIG) or subcutaneously (SCIG)
    Site of service — definition
    DefinitionSite of service = location where the drug is administered (physician office, infusion center, home infusion, hospital-based outpatient).
    Preferred sitesPhysician's office, infusion center, home infusion, hospital-based outpatient setting

    Policy Revision History

    2026-08-01policy_revisionLatest

    Policy revised with new effective date (Effective Aug 1, 2026).

    2026-08-01clarification

    Clarified that Site of Service Medical Necessity criteria do NOT apply to Alaska fully insured members; infusion/injection drug criteria apply instead.

    Policy Summary
    PayerPremera Bluecross
    PolicyImmune Globulin Therapy (IVIG/SCIG) Coverage and Site-of-Service Criteria
    Policy CodePolicy 8.01.503
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document diagnosis, age/platelet counts (for ITP), disease severity, and prior inadequate response to conventional agents when requesting IVIG.
    SourceLink
    On This Page
    Coverage Criteria for Immune Globulin (IVIG/SCIG)Drugs Subject to Site-of-Service Review and Clinical ThresholdsPrior Authorization, Documentation, and Denial RisksBackground on Immune Globulin TherapyDefinitions and Key TermsPolicy Revision History
    Clinical infection requirement: Persistent and severe infections despite treatment with prophylactic antibiotics.

    Clinical history requirement from policy

    Specific antibody deficiency (SAD) criteria: Normal serum IgG, IgG subclasses, IgA, and IgM AND normal responses to protein antigens (e.g., tetanus/diphtheria) measured 4 weeks after immunization AND inadequate responsiveness to pneumococcal polysaccharide vaccine (age‑specific thresholds: <50% protective serotypes if <6 years; <70% if ≥6 years) AND recurrent severe bacterial sinopulmonary infections despite pneumococcal vaccination and prophylactic antibiotics AND documented management of underlying asthma/allergic rhinitis.<50% serotypes protective if <6 yrs; <70% if ≥6 yrs

    Complete SAD criteria per policy

    Documented diagnosis required per policy

    Toxic shock syndrome (TSS): IVIG may be considered medically necessary when toxic shock syndrome is the documented diagnosis.

    Documented diagnosis required per policy

    Documentation note
    Age must be documented in clinical record for prior authorization
    Platelet count — ITP (adult) threshold
    Primary platelet thresholdPlatelet count less than 10,000/mm³
    Bleeding-risk contextThreshold applies when individual is considered at risk for severe or intracranial bleeding
    Documentation requirementRecent platelet count must be provided in clinical documentation
    Minimum age for adult IVIG statements
    Minimum age stated>= 18 years
    ScopeUsed throughout adult IVIG statements for ITP and related criteria
    Authorization implicationAge must be confirmed for prior authorization requests
    Platelet count threshold (repeated)
    ITP platelet threshold repeatedPlatelet count < 10,000/mm³
    Risk qualifierApplied when individual is at risk for severe or intracranial bleeding
    Alternate threshold noted elsewhereSome text references an alternate threshold of <30,000/mm³ in specific contexts
    Age for adult ITP (repeat)
    Adult ITP age requirement≥ 18 years
    Used for IVIG eligibilityApplies when determining IVIG medical necessity for ITP adults
    Must be documentedAge documented in request to avoid denial
    Platelet count — ITP (repeat)
    Platelet threshold (consensus)Platelet count < 10,000/mm³
    Contextual alternativeDocument also notes platelet <30,000/mm³ as an alternate referenced threshold in portions of policy
    Clinical actionProvide recent platelet count and bleeding-risk assessment for prior authorization
    Minimum age for adult IVIG / ITP statements (repeat)
    Adult age minimum>= 18 years
    Applicable indicationsSpecifically cited across IVIG ITP criteria and authorization sections
    Denial riskLack of age documentation for ITP may trigger denial
    Platelet count threshold (repeat)
    ITP platelet criterionPlatelet count < 10,000/mm³
    Bleeding-risk requirementThreshold coupled with individual considered at risk for severe/intracranial bleeding
    Authorization notePlatelet count must be recent and included in documentation
    Adult age threshold for ITP (repeat)
    Adult age threshold>= 18 years
    Policy usageConsistently required for IVIG coverage decisions in ITP adults
    Prior auth implicationConfirm age on requests to establish medical necessity
    Platelet count threshold for IVIG consideration in adult ITP
    Platelet threshold for IVIG considerationPlatelet count < 10,000/mm³
    Clinical qualifierUsed when individual is considered at risk for severe or intracranial bleeding
    DocumentationDocumented diagnosis of ITP and platelet values required
    Age threshold for adult ITP (repeat)
    Age threshold — adult ITP≥ 18 years
    Applies to IVIG coverageAge requirement appears repeatedly in ITP sections
    Record keepingAge should be recorded on authorization forms
    Platelet count threshold — primary and alternate
    Primary platelet thresholdPlatelet count < 10,000/mm³
    Alternate thresholdPolicy also references platelet count <30,000/mm³ as an alternate in some sections
    ContextThresholds apply when assessing risk for severe or intracranial bleeding
    Age threshold — adult (repeat)
    Adult age requirement≥ 18 years
    Used with platelet thresholdsAge combined with platelet count and bleeding-risk assessment for IVIG decisions
    Required for prior authorizationDocumentation should include age to meet criteria
    Platelet count threshold — primary and alternate mentions
    Platelet threshold reiteratedPlatelet count < 10,000/mm³ (alternate mentions of <30,000/mm³)
    Clinical applicationThresholds used to justify IVIG when bleeding risk exists
    Documentation guidanceProvide platelet counts and bleeding-risk assessment for review
    Age threshold — adult (repeat)
    Adult age cutoff>= 18 years
    Consistent policy elementRepeated across adult ITP coverage statements
    Authorization noteAbsence of age documentation risk for denial
    Platelet count thresholds for adult ITP
    ITP platelet count thresholdsPrimary: <10,000/mm³; Alternate referenced: <30,000/mm³
    Bleeding-risk qualifierPrimary threshold applied when individual is at risk for severe or intracranial bleeding
    Evidence requirementRecent platelet counts must be submitted for prior authorization
    Age threshold — adult ITP (repeat)
    Adult age threshold repeated≥ 18 years
    Applied across ITP coverage rulesUsed with numeric platelet thresholds to determine IVIG necessity
    Documentation importanceConfirm age in clinical record to support request

    Prior authorization: autoimmune blistering diseases

    Prior authorization requests for autoimmune mucocutaneous blistering diseases must demonstrate the specific diagnosis, that disease is severe and progressive, and that conventional agents were tried with inadequate response.

    • Specify the blistering diagnosis (e.g., bullous pemphigoid, mucous membrane pemphigoid, pemphigus subtypes)
    • Document severe progressive disease and prior inadequate response to corticosteroids and immunosuppressives
    Prior Authorization

    Prior authorization expected for listed IVIG indications

    Prior authorization is expected when IVIG is requested for the listed autoimmune mucocutaneous blistering diseases or specified infectious/toxic conditions and must include supporting documentation that policy criteria are met.

    • Include diagnosis-specific documentation for infectious indications (e.g., measles PEP, parvovirus B19, TSS)
    • For autoimmune indications, include severity and prior therapy details
    Prior Authorization

    Prior authorization required for ITP

    Prior authorization is required when IVIG is requested for adult immune thrombocytopenia (ITP); the request must document the diagnosis and the clinical circumstances per policy criteria.

    • Documented diagnosis of ITP in an adult
    • Provide platelet counts and bleeding-risk assessment as applicable
    Prior Authorization

    Prior authorization: age and platelet requirements for adult ITP

    When requesting IVIG for adult ITP, prior authorization must document that the patient is ≥18 years and meets platelet-count criteria as stated in the policy.

    • Age ≥ 18 years
    • Platelet count threshold (policy references <10,000/mm³ primary; alternative mentions of <30,000/mm³ in parts of the text)
    Prior Authorization

    Prior authorization must document diagnosis and criteria

    Prior authorization must establish medical necessity by documenting the diagnosis and that the individual meets the stated criteria (e.g., age for ITP, failed conventional therapy for blistering diseases, or documented TSS).

    • Provide diagnosis and relevant numeric or clinical thresholds
    • Show prior therapy history when required
    Documentation Required

    Document diagnosis and criteria (age, platelet count, prior therapies)

    Medical necessity for IVIG requires documentation of the diagnosis and fulfillment of the policy criteria, including adult age where specified, recent platelet count for ITP, and prior therapies for blistering diseases.

    • Age (≥18) for adult ITP
    • Recent platelet count showing policy-specified threshold
    • Evidence of prior trial and inadequate response to conventional agents for blistering diseases
    Prior Authorization

    Prior authorization: document that policy criteria are met

    Prior authorization requests must show that policy criteria are met for the referenced indications (e.g., agammaglobulinemia thresholds for immunodeficiency, platelet-count thresholds for ITP, or documented severe progressive disease for blistering diseases).

    • Laboratory thresholds for immunodeficiency (e.g., IgG cutoffs) when applicable
    • Documentation of severe progressive disease plus failed conventional therapy for blistering diseases
    • Platelet counts per ITP thresholds
    Prior Authorization

    Prior authorization and documentation required for listed conditions

    Prior authorization and documentation are implied for IVIG when used for listed conditions; submit supporting records that demonstrate the diagnosis and that clinical criteria are satisfied.

    • Attach medical records showing the documented diagnosis
    • Include lab values and prior-treatment notes as appropriate
    Prior Authorization

    Prior authorization: adult status, platelet count, bleeding risk for ITP

    Prior authorization for adult ITP must document that the patient is ≥18 years, has platelet counts below policy thresholds, and that the patient is at risk for severe or intracranial bleeding when platelet criteria are used.

    • Age ≥ 18 years
    • Platelet count < 10,000/mm³ (primary threshold) and assessment of bleeding risk
    Prior Authorization

    Prior authorization: documentation for adult ITP and severe blistering disease

    Prior authorization for IVIG in the listed indications requires documentation of the adult ITP platelet count <10,000/mm³ (or alternate threshold referenced) or documentation of severe blistering disease meeting policy criteria.

    • Document platelet counts and bleeding-risk assessment for ITP
    • Document severe progressive disease and prior inadequate response for blistering diseases
    Documentation Required

    Prior authorization: include age, platelet count, bleeding-risk or blistering severity

    Prior authorization requests must include diagnosis, age, recent platelet count, and either a bleeding‑risk assessment for ITP or documentation of severe progressive disease and prior inadequate response to conventional agents for blistering diseases.

    • Diagnosis and age (≥18 for ITP)
    • Recent platelet count and bleeding-risk assessment
    • Evidence of prior trials and inadequate response to corticosteroids/immunosuppressives for blistering diseases
    Prior Authorization

    Prior authorization: clinical criteria required for adult ITP

    Prior authorization requires clinical documentation demonstrating the individual is an adult (≥18 years) and meets platelet-count and bleeding-risk thresholds when IVIG is requested for ITP.

    • Age ≥ 18 years
    • Platelet count consistent with policy thresholds (<10,000/mm³ primary or <30,000/mm³ as an alternate mention)
    • Assessment of risk for severe or intracranial bleeding
    Prior Authorization

    Prior authorization: document numeric thresholds or severity/prior therapy failure

    Prior authorization is required with documentation of diagnosis and evidence that the individual meets the numeric platelet thresholds or disease-severity/prior-therapy failure criteria per the policy.

    • Document diagnosis
    • Provide platelet counts demonstrating threshold
    • For blistering diseases, document severe progressive disease and failed conventional agents
    Step Therapy

    Step requirement: inadequate response to conventional agents before IVIG

    For certain autoimmune mucocutaneous blistering diseases, IVIG is considered medically necessary only after an inadequate response to conventional agents such as corticosteroids and immunosuppressives has been documented.

    • Document trial(s) of corticosteroids and immunosuppressive agents
    • Show inadequate clinical response to those agents
    Step Therapy

    Step therapy: prior inadequate response required for blistering diseases

    Prior authorization for autoimmune blistering diseases requires documentation that conventional therapies were tried and were inadequate before IVIG is considered.

    • List specific conventional therapies attempted
    • Provide clinical notes showing insufficient response
    Step Therapy

    Step requirement: trials of corticosteroids and immunosuppressives

    Step therapy expectations include documentation of trials and inadequate response to conventional agents (corticosteroids and immunosuppressives) prior to IVIG for autoimmune mucocutaneous blistering diseases.

    • Corticosteroids trial documented
    • Immunosuppressive agents (examples: azathioprine, cyclophosphamide, mycophenolate) trial documented
    Step Therapy

    Step therapy: required trials of listed conventional agents

    The policy requires documented trial and inadequate response to conventional agents (including corticosteroids and immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate) before IVIG is considered medically necessary for blistering diseases.

    • Specify agents tried (examples provided in policy)
    • Document duration and outcome of those trials
    Step Therapy

    Step therapy — autoimmune blistering diseases require prior inadequate response

    IVIG for autoimmune mucocutaneous blistering diseases is considered medically necessary only after inadequate response to conventional agents such as corticosteroids and immunosuppressants has been documented.

    • Document severe progressive disease
    • Document failure of conventional therapy
    Step Therapy

    Step therapy: severe progressive disease plus failed conventional therapy required

    For autoimmune mucocutaneous blistering diseases, IVIG is considered only when the individual has severe progressive disease and has tried and had an inadequate response to conventional agents (corticosteroids and immunosuppressives).

    • Confirm severe progressive disease in clinical notes
    • Provide records of conventional-agent trials and outcomes
    Step Therapy

    Step therapy: prior trial and inadequate response required

    Prior inadequate response to conventional agents (corticosteroids, immunosuppressives such as azathioprine, cyclophosphamide, mycophenolate) must be documented before IVIG for blistering diseases will be considered.

    • Document specific agents and treatment dates
    • Supply clinician assessment of inadequate response
    Step Therapy

    Step therapy requirement repeated for blistering diseases

    IVIG is medically necessary for autoimmune mucocutaneous blistering diseases only after trials of conventional agents have failed; the policy repeats this requirement throughout the document.

    • Ensure prior-therapy documentation is included with the authorization request
    Step Therapy

    Step therapy: pemphigoid/pemphigus require prior conventional-agent failure

    For pemphigoid and pemphigus variants, IVIG is considered medically necessary only after trial and inadequate response to conventional agents (examples: corticosteroids, azathioprine, cyclophosphamide, mycophenolate).

    • Document conventional-agent trials and response
    • List examples of immunosuppressives tried
    Step Therapy

    Step therapy: prior trials required (repeated)

    The policy repeatedly instructs that conventional-agent failure must be documented before IVIG is considered for autoimmune mucocutaneous blistering diseases.

    • Provide timeline of treatments and evidence of inadequate response
    Step Therapy

    Step therapy: examples of conventional agents to document

    Examples of conventional immunosuppressive agents that should be documented as tried and inadequate include azathioprine, cyclophosphamide, and mycophenolate.

    • List specific agents (azathioprine, cyclophosphamide, mycophenolate) and treatment details in the record
    Step Therapy

    Step therapy: document failed conventional agents (repeated instruction)

    The policy reiterates that conventional agent failure is required before IVIG for autoimmune mucocutaneous blistering diseases; include documentation of those failed trials in the prior-authorization packet.

    • Attach prior-treatment notes, dosing, and assessments of response
    Step Therapy

    Step therapy: repeated instruction for blistering diseases

    The requirement that conventional agents be tried and found inadequate before IVIG for autoimmune mucocutaneous blistering diseases is reiterated multiple times; ensure records clearly show these trials and outcomes.

    • Make prior-treatment documentation explicit and easy to review
    Step Therapy

    Step therapy: repeated requirement across policy

    Step-therapy instructions for autoimmune mucocutaneous blistering diseases are repeated throughout the policy; prior conventional-agent failure is a consistent requirement before IVIG will be considered.

    • Include documentation of severity and prior inadequate response in authorization requests
    Step Therapy

    Step therapy: repeated requirement (final excerpt)

    The policy's repeated statements emphasize that IVIG for autoimmune mucocutaneous blistering diseases is considered only after inadequate response to conventional agents; include clear prior-therapy records.

    • Document prior use of corticosteroids and listed immunosuppressives and outcomes
    Documentation Required

    Required lab documentation: IgG levels and vaccine-response evidence

    Required clinical and laboratory documentation includes laboratory evidence of immunoglobulin deficiency (IgG levels and, where applicable, repeat measurements or inability to mount vaccine response) and documentation of recurrent or severe infections when indicated.

    • Provide IgG values and repeat testing if referenced
    • Include vaccine-response testing or explanation of inability to mount response when applicable
    Documentation Required

    Required documentation: diagnosis for infectious/toxic indications

    Documented diagnosis is required for indications such as measles post-exposure prophylaxis, severe anemia due to parvovirus B19, and toxic shock syndrome; include the diagnostic evidence in the prior-authorization submission.

    • Attach diagnostic test results or clinician diagnosis notes for measles PEP, parvovirus B19 anemia, or TSS
    Documentation Required

    Required clinical documentation: diagnosis, severity, prior inadequate response

    Clinical documentation must show the diagnosis, disease severity, and prior inadequate response to conventional agents when applicable; include specific clinical notes supporting those elements.

    • For blistering diseases: diagnosis, severity, and prior-treatment failure
    • For ITP: diagnosis, age, platelet counts, and bleeding-risk assessment
    Documentation Required

    Required documentation: list specific blistering diagnoses

    Documentation should include the specific covered diagnosis (e.g., bullous pemphigoid, mucous membrane pemphigoid, pemphigus variants) and supporting evidence of severe progressive disease and prior inadequate response to conventional therapies.

    • List the specific pemphigoid/pemphigus subtype
    • Attach clinician assessments documenting progression and treatment failure
    Documentation Required

    Diagnosis-specific documentation required

    Documentation must identify the referenced condition (parvovirus B19 anemia, TSS, ITP, or autoimmune blistering disease) and include the evidence required by policy to support IVIG use.

    • Include diagnosis and the specific evidence that meets policy criteria
    Documentation Required

    Document diagnosis for referenced infectious conditions

    Documented diagnosis is required for the listed conditions (for example, human parvovirus B19) and must be included with the authorization request.

    • Provide laboratory or clinical documentation confirming the diagnosis
    Documentation Required

    Required documentation: diagnosis, age, platelet count, prior therapy evidence

    Medical record documentation should include diagnosis, age, recent platelet count, and evidence of prior therapies (and inadequate response) where required by the indication.

    • Include age and platelet-count values for ITP
    • Attach prior-treatment notes for blistering diseases
    Documentation Required

    Required documentation: age, platelet count, bleeding-risk for ITP

    Documentation must include age (≥18 for adult ITP), recent platelet counts demonstrating the policy threshold (primary <10,000/mm³; alternate mentions <30,000/mm³), and an assessment of bleeding risk when applicable.

    • Age documentation
    • Recent platelet count values
    • Bleeding-risk assessment or clinician rationale
    Documentation Required

    Required clinical documentation: diagnosis, severity, prior trials, platelet counts

    Clinical documentation must include the diagnosis, disease severity (severe progressive disease for blistering diseases), prior trials and inadequate response to conventional agents, and platelet counts/bleeding risk for ITP.

    • Diagnosis and severity notes for blistering diseases
    • Records of conventional-agent trials and outcomes
    • Platelet counts and bleeding-risk assessment for ITP
    Documentation Required

    Required documentation: evidence conventional agents were tried and inadequate

    Documentation must show that conventional agents (e.g., corticosteroids and immunosuppressive agents such as azathioprine, cyclophosphamide, mycophenolate) were tried and had inadequate response for blistering diseases prior to IVIG.

    • List specific agents tried and clinical response
    • Provide durations and clinician assessment of inadequate response
    Denial Risk

    Denial risk if policy criteria not documented

    Requests lacking documentation of meeting the policy criteria (age for ITP, platelet-count threshold, severe progressive blistering disease, or prior inadequate response to conventional agents) may be denied.

    • Include all required clinical and laboratory evidence to avoid denial
    Denial Risk

    Denial risk for site-of-service mismatch

    Site-of-service mismatch can lead to denial: use of outpatient hospital IV infusion when the policy's site-of-service criteria are not met may be considered not medically necessary.

    • Follow site-of-service guidance (preferred outpatient sites for initial 90 days, exceptions when medically necessary)
    Denial Risk

    Denial risk: missing severity or prior-treatment documentation for blistering diseases

    Lack of documentation that disease is severe and progressive or that conventional agents were tried and inadequate for autoimmune mucocutaneous blistering diseases may result in denial of IVIG requests.

    • Provide clear clinical evidence of progression and treatment failure
    Denial Risk

    Denial risk: missing age or platelet evidence for adult ITP

    Requests for IVIG for adult ITP may be denied if the request does not document that the patient is ≥18 years or that the platelet-count threshold (<10,000/mm³, or alternate <30,000/mm³ where referenced) and bleeding-risk criteria are met.

    • Confirm age and include recent platelet counts and bleeding-risk rationale
    Denial Risk

    Denial risk: missing diagnostic indication

    Requests lacking documentation of the diagnostic indication (e.g., ITP, TSS, autoimmune mucocutaneous blistering disease) risk denial; always include the documented diagnosis in the submission.

    • Attach diagnostic notes or test results confirming the indication
    Denial Risk

    Denial risk: missing prior-treatment documentation for blistering diseases

    Failure to document prior treatment trials (corticosteroids and immunosuppressives) and inadequate response for blistering diseases may result in denial of IVIG requests.

    • Provide records of prior therapies and clinician assessment of inadequate response
    Denial Risk

    Denial risk: ITP platelet threshold not met

    If ITP threshold criteria are not met (no documentation of age ≥18 and platelet count <10,000/mm³ or applicable alternate threshold), IVIG requests for adult ITP may be denied or considered not medically necessary.

    • Include explicit platelet-count values and age in the record to meet threshold
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    First 90 days policyOutpatient infusion at preferred sites considered medically necessary for initial course or re-initiation after ≥6 months
    Conventional agents / immunosuppressive agents — examples
    Examples listedAzathioprine, cyclophosphamide, mycophenolate
    Class descriptionConventional immunosuppressive agents referenced as prior therapies to be tried before IVIG for blistering diseases
    ContextRequired trial and inadequate response to these agents supports IVIG consideration
    Autoimmune mucocutaneous blistering diseases — definition and examples
    DefinitionAutoimmune mucocutaneous blistering diseases include pemphigoid (bullous pemphigoid, mucous membrane pemphigoid) and pemphigus (pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus).
    IVIG roleIVIG may be considered when disease is severe, progressive, and refractory to conventional agents
    Documentation neededDocumented diagnosis, disease severity, and failed conventional therapy required for authorization
    Conventional agents — corticosteroids and immunosuppressive examples
    Conventional agents examplesCorticosteroids plus immunosuppressives (azathioprine, cyclophosphamide, mycophenolate)
    Step requirementTrial and inadequate response to these agents required before IVIG is considered medically necessary for blistering diseases
    DocumentationClinical record should show prior therapies and inadequate response
    Severe progressive disease — policy usage
    Usage as criterion'Severe progressive disease' is used as a required criterion for IVIG consideration for autoimmune mucocutaneous blistering diseases
    Not explicitly definedTerm is not numerically or operationally defined in the policy text and requires clinical documentation
    Documentation implicationProvider must document disease severity and progression in records for prior authorization
    Conventional agents — repeated examples
    Repeated examplesAzathioprine, cyclophosphamide, mycophenolate
    RoleListed as conventional immunosuppressive agents that should be tried before IVIG for blistering diseases
    Evidence requirementDocument prior trial and inadequate response to these agents in clinical records
    Autoimmune mucocutaneous blistering diseases — repeated definition
    Definition repeatedAutoimmune mucocutaneous blistering diseases include pemphigoid (bullous, mucous membrane) and pemphigus (vulgaris, foliaceus, IgA, paraneoplastic)
    Indication for IVIGIVIG may be considered when disease is severe/progressive and refractory to conventional therapies
    Subtypes listedBullous pemphigoid; mucous membrane pemphigoid; pemphigus vulgaris; pemphigus foliaceus; IgA pemphigus; paraneoplastic pemphigus
    Autoimmune mucocutaneous blistering diseases — variants and coverage
    Autoimmune blistering variantsPemphigoid and pemphigus subtypes (bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus)
    Coverage conditionIVIG considered medically necessary when severe progressive disease AND inadequate response to conventional agents are documented
    Prior therapy examplesCorticosteroids and immunosuppressives (azathioprine, cyclophosphamide, mycophenolate)
    Immune thrombocytopenia — definition and coverage note
    DefinitionImmune thrombocytopenia (ITP) formerly idiopathic thrombocytopenic purpura; autoimmune condition causing low platelet counts
    Coverage noteIVIG may be medically necessary for adults (≥18 years) with platelet counts <10,000/mm³ or per alternate sections <30,000/mm³ when at risk for severe bleeding
    Documentation requiredDocument diagnosis, age, platelet counts, and bleeding-risk assessment for prior authorization
    Autoimmune mucocutaneous blistering diseases — listed variants
    Pemphigoid/pemphigus listingIncludes bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, paraneoplastic pemphigus
    IVIG criteriaSevere progressive disease AND prior inadequate response to corticosteroids and immunosuppressives required
    Examples of conventional agentsAzathioprine, cyclophosphamide, mycophenolate
    Autoimmune mucocutaneous blistering diseases — additional notes
    Additional variants notedPolicy repeats pemphigoid and pemphigus subtypes across sections
    Treatment pathwayRequires trial and inadequate response to conventional agents before IVIG is considered
    Provider requirementDocument prior therapies and disease progression in records
    Immune thrombocytopenia (ITP) — Adults definition
    Adult ITP definitionAdults (≥18 years) with platelet count less than 10,000/mm³ and considered at risk for severe or intracranial bleeding
    Policy applicationDefines scenario where IVIG may be medically necessary for ITP adults
    DocumentationDocumented diagnosis and platelet counts required for prior authorization
    Toxic shock syndrome (TSS) — definition and indication
    Toxic shock syndrome (TSS) as indicationTSS is listed as a documented diagnosis for which IVIG may be considered medically necessary
    Documentation requirementA documented diagnosis of TSS is required to consider IVIG
    Placement in policyTSS included alongside infectious and autoimmune indications
    Autoimmune mucocutaneous blistering diseases — repeated definition
    Repeat listingPemphigoid and pemphigus subtypes repeatedly listed across policy sections
    IVIG criteria restatedSevere progressive disease plus inadequate response to conventional agents required
    Conventional agents examplesCorticosteroids, azathioprine, cyclophosphamide, mycophenolate
    Immune thrombocytopenia (ITP) - Adults — policy summary
    ITP adult criteria summaryAge ≥18 years AND platelet count <10,000/mm³ with risk for severe/intracranial bleeding; documented diagnosis required
    Repeated across policyThis numeric threshold and age requirement appear throughout the document
    Provider actionEnsure platelet counts and bleeding-risk assessment are included in prior authorization packet
    TSS — repeated indication note
    TSS repeatedToxic shock syndrome repeatedly noted as a documented diagnosis indication for IVIG
    No numeric thresholdsTSS indication requires only documented diagnosis rather than numeric lab thresholds
    DocumentationClinical diagnosis documentation needed for prior authorization
    Autoimmune mucocutaneous blistering diseases — repeated variants
    Autoimmune blistering groupsPemphigoid and pemphigus groups encompass multiple subtypes listed for IVIG consideration
    Severity/prior therapy requirementSevere progressive disease and prior inadequate response to conventional agents required
    Examples of subtypesBullous pemphigoid; mucous membrane pemphigoid; pemphigus vulgaris; pemphigus foliaceus; IgA pemphigus; paraneoplastic pemphigus
    Immune thrombocytopenia (ITP) — Adults — policy threshold summary
    ITP adult criterion repeatedIndividual aged ≥18 years with platelet count <10,000/mm³ and at risk for severe bleeding — IVIG may be medically necessary
    Alternate platelet mentionSome sections reference platelet <30,000/mm³ as an alternate threshold
    Documentation neededDocumented diagnosis and platelet counts required for authorization
    TSS — policy listing
    TSS documented indicationToxic shock syndrome is a listed indication when documented
    Clinical requirementProvide documentation of TSS diagnosis for prior authorization
    PlacementListed among infectious and autoimmune indications for IVIG
    Autoimmune mucocutaneous blistering diseases — variants (repeated)
    Pemphigoid/pemphigus variants listedBullous pemphigoid; mucous membrane pemphigoid; pemphigus vulgaris; pemphigus foliaceus; IgA pemphigus; paraneoplastic pemphigus
    IVIG criteriaSevere progressive disease plus inadequate response to corticosteroids/immunosuppressives required
    Examples of immunosuppressivesAzathioprine, cyclophosphamide, mycophenolate
    Immune thrombocytopenia (ITP) — Adults — repeated policy note
    ITP definition for adultsAdults (≥18 years) with platelet count <10,000/mm³ and considered at risk for severe or intracranial bleeding; documented diagnosis required
    Clinical implicationThreshold used to determine medical necessity for IVIG in ITP adults
    Provider requirementSubmit platelet counts and bleeding-risk assessment with request
    Autoimmune mucocutaneous blistering diseases — final repeats
    Autoimmune blistering variants (final repeats)Pemphigoid and pemphigus subtypes repeatedly enumerated across document
    IVIG coverage conditionsSevere progressive disease and failed conventional therapy required
    Documentation noteProvide evidence of prior therapies and inadequate response
    Immune thrombocytopenia (ITP) and autoimmune blistering diseases — summary
    ITP summaryAdult ITP: age ≥18 and platelet count <10,000/mm³ (or <30,000/mm³ as alternate) with risk for severe bleeding — IVIG may be medically necessary
    Autoimmune blistering summarySevere progressive disease and inadequate response to conventional agents required for IVIG consideration
    Documentation requiredDocument diagnosis, age, platelet counts, prior therapies, and bleeding-risk assessment
    Immune thrombocytopenia (ITP) — Adults (final) and documentation
    ITP adult definition (final)ITP in individuals aged 18 years or older; document platelet counts and bleeding risk per policy thresholds
    Actionable itemsProvide platelet counts (<10,000/mm³ primary; <30,000/mm³ alternate) and bleeding-risk assessment for IVIG prior authorization
    Autoimmune blistering actionDocument severe progressive disease and failed trials of corticosteroids/immunosuppressives